

# MEDICINE MAN TECHNOLOGIES, INC.

## FORM 10-Q (Quarterly Report)

Filed 08/17/17 for the Period Ending 06/30/17

Address	4880 HAVANA STREET SUITE 102 SOUTH DENVER, CO, 80239
Telephone	303-371-0387
CIK	0001622879
Symbol	MDCL
SIC Code	8742 - Services-Management Consulting Services
Industry	Pharmaceuticals
Sector	Healthcare
Fiscal Year	12/31

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **June 30, 2017**

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_.

Commission File Number: **000-55450**

**Medicine Man Technologies, Inc.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or Other Jurisdiction of  
Incorporation or Organization)

**46-5289499**

(IRS Employer  
Identification Number)

**4880 Havana Street  
Suite 201**

**Denver, Colorado**

(Address of principal executive offices)

**80239**

(Zip Code)

Registrant's telephone number, including area code: **(303) 371-0387**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer

Non-accelerated filer

Emerging growth company

Accelerated filer

Smaller reporting company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of August 15, 2017, there were 18,992,238 shares of common stock, par value \$0.001 issued and outstanding.

**MEDICINE MAN TECHNOLOGIES, INC.**  
**Table of Contents**

	<b><u>Page</u></b>
<b><u>Part I – FINANCIAL INFORMATION</u></b>	
Item 1. <a href="#">Financial Statements</a>	4
Item 2. <a href="#">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a>	23
Item 3. <a href="#">Quantitative and Qualitative Disclosures about Market Risk</a>	25
Item 4. <a href="#">Controls and Procedures</a>	26
<b><u>Part II – OTHER INFORMATION</u></b>	
Item 1. <a href="#">Legal Proceedings</a>	27
Item 1A. <a href="#">Risk Factors</a>	27
Item 2. <a href="#">Unregistered Sales of Equity Securities and Use of Proceeds</a>	27
Item 3. <a href="#">Defaults upon Senior Securities</a>	27
Item 4. <a href="#">Mine safety disclosure</a>	27
Item 5. <a href="#">Other Information</a>	27
Item 6. <a href="#">Exhibits</a>	27

### ***CAUTIONARY STATEMENT ON FORWARD-LOOKING INFORMATION***

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that a statement is not forward-looking. This information may involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by any forward-looking statements.

Factors that may cause or contribute actual results to differ from these forward-looking statements include, but are not limited to, for example:

- adverse economic conditions;
- the inability to attract and retain qualified senior management and technical personnel;
- other risks and uncertainties related to the cannabis market and our business strategy.

All forward-looking statements speak only as of the date of this report. We undertake no obligation to update any forward-looking statements or other information contained herein. Stockholders and potential investors should not place undue reliance on these forward-looking statements. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved. We disclose important factors that could cause our actual results to differ materially from expectations under “Risk Factors” in our Form 10-K. These cautionary statements qualify all forward-looking statements attributable to us or persons acting on our behalf.

These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. Considering these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the Quarterly Report on Form 10-Q. All subsequent written and oral forward-looking statements concerning other matters addressed in this Quarterly Report on Form 10-Q and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Quarterly Report on Form 10-Q.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether because of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

**PART I - FINANCIAL INFORMATION**

## Item 1. Financial Statements

**MEDICINE MAN TECHNOLOGIES, INC.**  
**BALANCE SHEETS**  
*Expressed in U.S. Dollars*

	<u>June 30, 2017</u>	<u>December 31, 2016</u>
<b>Assets</b>		
<b>Current assets</b>		
Cash and cash equivalents	\$ 200,600	\$ 351,524
Accounts receivable, net	231,399	25,000
Accounts receivable - related party	24,294	-
Available for sale securities	17,701	13,998
Short-term note receivable	278,893	264,016
Inventory	109,174	-
Other assets	50,006	27,479
Total current assets	912,067	682,017
<b>Non-current assets</b>		
Fixed assets, net accumulated depreciation of \$46,278	\$ 154,033	\$ 42,126
Intangible assets, net accumulated amortization of \$3,055	72,869	3,708
Goodwill	6,301,080	-
Total non-current assets	6,527,982	45,834
Total assets	\$ 7,440,049	\$ 727,851
<b>Liabilities and Stockholders' Equity</b>		
<b>Current liabilities</b>		
Accounts payable	\$ 32,328	\$ -
Derivative liability	23,017	294,002
Other liabilities	10,713	175
Total current liabilities	66,058	294,177
<b>Long-term liabilities</b>		
Note payable - related party	\$ 58,280	\$ -
Convertible loan	675,000	810,000
Total long-term liabilities	733,280	810,000
Total liabilities	799,338	1,104,177
<b>Commitments and contingencies, note 13</b>		
<b>Shareholders' equity</b>		
Common stock \$0.001 par value, 90,000,000 authorized, 18,948,087 and 10,402,500 were issued and outstanding June 30, 2017 and December 31, 2016, respectively.	\$ 19,118	\$ 10,403
Additional paid-in capital	10,327,876	1,026,052
Additional paid-in capital - Warrants	2,100,318	-
Accumulated other comprehensive income (loss)	(14,854)	(4,303)
Retained earnings	(5,791,747)	(1,408,478)
Total shareholders' equity	6,640,711	(376,326)
Total liabilities and stockholders' equity	\$ 7,440,049	\$ 727,851

See accompanying notes to the financial statements

**MEDICINE MAN TECHNOLOGIES, INC.**  
**STATEMENT OF COMPREHENSIVE (LOSS) AND INCOME**  
**(UNAUDITED)**

*For the Three and Six Months Ended June 30, 2017 and 2016*  
*Expressed in U.S. Dollars*

	<u>Three Months Ended June 30,</u>		<u>Six Months Ended June, 30</u>	
	<u>2017</u>	<u>2016</u>	<u>2017</u>	<u>2016</u>
<b>Operating revenues</b>				
Product sales	\$ 229,214	\$ –	\$ 229,214	\$ –
Product sales - related party	122,944	–	122,944	–
Licensing fees	301,313	142,986	501,313	337,221
Consulting fees	226,582	–	565,796	\$ –
Seminar fees	2,300	6,780	4,222	12,160
Total revenue	<u>882,353</u>	<u>149,766</u>	<u>1,423,489</u>	<u>349,381</u>
<b>Cost of services</b>				
Cost of services	\$ 245,965	\$ 44,177	\$ 411,124	\$ 181,618
Cost of services - related party	26,036	–	26,036	–
Total cost of services	<u>272,001</u>	<u>44,177</u>	<u>437,160</u>	<u>181,618</u>
<b>Gross profit</b>	<u>\$ 610,352</u>	<u>\$ 105,589</u>	<u>\$ 986,329</u>	<u>\$ 167,763</u>
<b>Operating expenses</b>				
General and administrative	\$ 331,425	\$ 197,879	\$ 435,296	\$ 312,217
Professional services	141,953	–	233,483	–
One-time Acquisition costs	98,701	–	98,701	–
Stock based compensation expense	4,480,318	–	4,480,318	49,200
Advertising	56,025	9,180	89,509	21,672
Salaries	64,447	–	64,447	–
Total operating expenses	<u>\$ 5,172,869</u>	<u>\$ 207,059</u>	<u>\$ 5,401,754</u>	<u>\$ 383,089</u>
<b>Income from operations</b>	<u>\$ (4,562,517)</u>	<u>\$ (101,470)</u>	<u>\$ (4,415,425)</u>	<u>\$ (215,326)</u>
<b>Other income/expense</b>				
Interest income	\$ (7,480)	\$ (1,808)	\$ (14,877)	\$ (1,808)
Net gain on derivative	(82,373)	–	(131,382)	–
Interest expense related to convertible notes	21,990	–	44,329	–
Loss on management fee contracts	–	–	70,257	–
Net unrealized (loss) on available for sale securities	–	–	(262)	–
Other income	(219)	–	(219)	–
Total other expense	<u>(68,082)</u>	<u>(1,808)</u>	<u>(32,154)</u>	<u>(1,808)</u>
<b>Net income (loss)</b>	<u>\$ (4,494,435)</u>	<u>\$ (99,662)</u>	<u>\$ (4,383,271)</u>	<u>\$ (213,518)</u>
<b>Earnings per share attributable to common shareholders:</b>				
Basic and diluted (loss)/earnings per share	\$ (0.23)	\$ (0.01)	\$ (0.22)	\$ (0.02)
Weighted average number of shares outstanding - basic and diluted	19,548,087	10,092,500	19,548,087	10,031,875
<b>Other comprehensive income (loss), net of tax</b>				
Net unrealized (loss) on available for sale securities	(9,248)	(16,000)	(10,551)	(5,600)
Total other comprehensive income (loss), net of tax	<u>(9,248)</u>	<u>(16,000)</u>	<u>(10,551)</u>	<u>(5,600)</u>
<b>Comprehensive gain (loss)</b>	<u>\$ (4,503,683)</u>	<u>\$ (115,662)</u>	<u>\$ (4,393,822)</u>	<u>\$ (219,118)</u>

See accompanying notes to the financial statements

**MEDICINE MAN TECHNOLOGIES, INC.**  
**STATEMENT OF CASH FLOWS**  
**(UNAUDITED)**  
*For the Six Months Ended June 30, 2017 and 2016*  
*Expressed in U.S. Dollars*

	<u>2017</u>	<u>2016</u>
<b>Cash flows from operating activities</b>		
Net income for the period	\$ (4,383,271)	\$ (213,518)
Adjustments to reconcile net income to net cash provided by operating activities		
Loss (gain) on derivative, net	(131,382)	-
Stock based compensation	4,480,318	49,200
Depreciation and amortization	24,822	8,531
Changes in operating assets and liabilities		
Short term note receivable	(14,877)	(100,000)
Accounts receivable	(230,693)	70,447
Inventory	(109,174)	-
Other assets	(83,085)	(26,765)
Accounts payable and other liabilities	99,725	(12,429)
<b>Net cash used from operating activities</b>	<u>(347,617)</u>	<u>(224,534)</u>
<b>Cash flows from investing activities</b>		
Purchase of assets	\$ (205,890)	\$ -
Proceeds from AFS securities, net	(10,551)	-
Acquisition investment	233,357	-
<b>Net cash earned in investing activities</b>	<u>16,916</u>	<u>-</u>
<b>Cash flows from financing activities</b>		
Cash raised by sale of convertible debt	179,777	-
<b>Net cash earned for financing activities</b>	<u>179,777</u>	<u>-</u>
Net decrease in cash and cash equivalents	\$ (150,924)	\$ (224,534)
Cash and cash equivalents - beginning of year	351,524	262,146
<b>Cash and cash equivalents - end of year</b>	<u>\$ 200,600</u>	<u>\$ 37,612</u>
<b>Non-Cash Transactions</b>		
Acquisition investment	\$ 233,357	\$ -

See accompanying notes to the financial statements

**NOTES TO THE FINANCIAL STATEMENTS**  
**(UNAUDITED)**

**Organization and Nature of Operations:**

Business Description – Business Activity: Medicine Man Technologies Inc. (the "Company") is a Nevada corporation incorporated on March 20, 2014. The Company is a cannabis consulting company providing services related to cost efficient cannabis cultivation technologies focusing on quality as well as safety, retail operations related to the delivery of cannabis related products, and other related business lines as described in our operating strategic vision outlines below.

Brand Warehouse Development – The Company intends to aggregate new business opportunities into its corporate fabric in a manner that does not diminish the various companies or brands it is partnering with, but rather enhances it. Suitable candidates for consideration will have ongoing operations within various industry segments, such as the Denver Consulting Group LLC. Over time, the Company expects to expand its presence within the industry through the development of an ‘intelligent acquisition’ process.

Intelligent Acquisition – This term is meant to define a selection and due diligence process that will enable both the Company as well as the acquisition to benefit mutually in that each may better 1) establish a more stable method of continual valuation through direct contact with the public marketplace wherein with the related growth of the enterprise as a whole it will eventually be able to achieve a national exchange listing status, 2) market themselves collectively thus taking advantage of certain cost savings strategies through shared participation in various events and advertising opportunities, 3) take advantage of other operating and reporting cost efficiencies available to the Company through aggregation of such acquisitions, 4) continue to work develop a full spectrum of products and services deliverable to the general cannabis marketplace through careful segmentation of the marketplace as a whole, and 5) continue to work collaboratively within the industry to achieve both transparency as well as a strong positive reputation for ethical behavior when working both internally within its collective as well as externally with others in the industry.

**Our Three Current Business Groups**

As we evolve our various business lines and branding strategies, we are working to align our service offerings into logical groupings (3 at this time) that will allow our potential clients as well as investors a better understanding of how we operate currently as well as into the future. In FY 2017, we intend to break down our income in the following groupings so that our shareholders as well as possible investors may have a better understanding of our general operations.

As the industry’s competitive landscape is very fluid and conditions within both new states as well as existing states with cannabis related regulations are everchanging, we price our services according to market conditions as well as competitive influences and are continually managing our pricing structures on a very frequent basis to insure a best rate to value ratio is clearly maintained.

Since general consulting and new state initiatives typically involve these elements and are generally related to the startup phase of any new cannabis business in a new state adopting either medical or adult use initiative, we have elected to include these elements in one grouping. The specifics of these newly established groups are as follows:

Education, Design, Business Plan, and New State Initiatives (Group 1)

*Private Consultation Services*

We expect these services to augment our existing Seminar offerings and over time replace most of our local seminar offerings all together.

*2-Hour Private Consulting Package*

This package is designed for individuals and business owners that are interested in becoming involved in the cannabis industry but need more guidance and personal consultation when working to advance their own goals and industry knowledge in order to increase their chances of success in this burgeoning industry. The 2-Hour Private Consultation Package includes a private One-on-One consultation with our consulting staff and/or ownership, as well as a private full tour of both our Medical and Adult Use Dispensary Operations and Medicine Man’s 40,000 square foot cultivation facility.

This package sets the foundation for groups considering entering the cannabis space by providing real world examples of projects and cannabis industry marketplaces that we have worked within to provide clients with fact based information from which to build their business outlooks from. The 2-Hour Private Consultation is also the main entry point for clients considering our services to have the opportunity to sit down with our team and learn more about our Licensing Services. Consultation fees collected are credited back to clients who proceed with our Full Licensing Packages.



Details:

- Initial phone call prior to consultation/tour to discuss client's outlook for client's future operations to prepare consulting team for client's upcoming visit
- 60-minute private consultation at Medicine Man Technologies Headquarters in Denver, CO.
- 60-minute private tour of Medicine Man Production Company's Dispensary and Cultivation Operations
- Monthly E-Newsletter with Cultivation, Dispensary and Investment Tips
- Exclusive invites to events, workshops and boot camps hosted by Medicine Man Technologies
- When Client is under contract by Medicine Man Technologies for Licensing Services, Client will be credited back their initial consultation fee to be applied towards their licensing fees.

Recommended for:

Individuals and business owners that need more guidance and personal consultation when working to advance their own goals in the cannabis industry and to increase their business's success.

*3-Hour Private Consulting Package*

Operating in the emerging cannabis industry requires experienced partners who can help Clients avoid costly mistakes. Our team of professional consultants help clients navigate the process of becoming successful cannabis operators. Using our personal experience, expertise and proven methods, Clients may avoid many of the costly pitfalls of entering and operating in the space and maximize their return on investment. This package includes a private One-on-One consultation with our consulting staff and/or Ownership, a private full tour of both our Medical and Adult Use Dispensary Operations and Medicine Man's 40,000 square foot cultivation facility, a basic Pro Forma to aid in Clients financial modeling, a copy of the Three-A-Light Cultivation Manual by Josh Haupt (a \$500 value), and a Success Nutrients Starter Kit (a \$320 Value).

Details:

- Initial phone call prior to consultation/tour to discuss client's outlook for client's future operations to prepare consulting team for client's upcoming visit
- 60-minute private consultation at our headquarters in Denver, CO.
- 60-minute private tour of Medicine Man Production Company's Dispensary and Cultivation Operations
- 60-minute private tour of the Three-A-Light cultivation facility
- Base pro forma to use for financial modeling purposes
- A Three-A-Light cultivation book/manual (\$500 value)
- Success Nutrients Starter Kit (a \$320 value)
- Monthly E-Newsletter with Cultivation, Dispensary and Investment Tips
- Exclusive invites to events, workshops and boot camps hosted by us
- When a client is under contract to receive our licensing services, a client will be credited back their initial consultation fee to be applied towards their licensing fees.

Recommended for: Individuals and business owners who:

Are current cannabis cultivators but are not producing the yields and consistency they could be and need guidance from our senior consultants and lead cultivation staff members on how to improve their performance and efficiencies ... or

Entrepreneurs who are interested in the cannabis industry and have the capital, connections and passion to become operators in the cannabis space but do not have intimate knowledge about the industry and need guidance in several areas in order to being the state licensure process. We provide these client groups with high level guidance as it pertains to such things as complex state application processes, facility design, financial modeling, security, cultivation methodologies, pesticide and nutrient management plans, dispensary operations, inventory management, packaging and labeling and much more.

*We also offer customized consulting services on a project needs basis related to :*

- Business Plan Generation
- Pitch Deck Generation
- Customized Bid Based Service Offerings, Specific State Regulation Based
- Others

### *Seminar Offering Services*

We offer seminars in emerging markets and at our facilities in Denver, CO. The crash course seminars are designed to educate participants about the requirements associated with becoming licensed operators in their own geographic market, and include guidance and tips on navigating:

- Industry opportunities
- Medical and Recreational Market Trends
- Cultivation Methodologies and Technology
- Processing Methodologies and Technology
- Extraction Technology
- Dispensary Operations
- Operating Pros and Cons
- Security Requirements
- Banking, Tax, and Finance
- Real Estate Planning and Tips
- License Application Planning and Tips
- Advocacy, Outreach, Lobbying

The Denver-based seminars end with a tour of Medicine Man's cultivation and dispensary facilities, allowing participants to get a first-hand view of a fully compliant medical and recreational cultivation and dispensary operation.

We have been asked to provide key support and informational segments for various local, regional, and national events and continues to work to maintain our industry presence through such event participation. We have already scheduled specialty seminars in North Carolina, Arkansas, Pennsylvania, and Michigan during FY 2017 and expects to add additional events throughout the year.

### *Facility Design*

We have experience designing indoor grows, greenhouse grows, and hybrid growing facilities as well as retail dispensaries. Our design team consists of an architect and a contracting firm that have a wealth of knowledge in the medical and recreational cannabis cultivation and retail space; having designed and constructed numerous facilities throughout the state of Colorado and other markets. Our team will collaborate with a client's local architect and general contractor to develop an optimal design and construction plan that will meet all IBC and zoning codes as well as support the Variable Capacity Continuous Harvest model. Our team will provide all reference drawings, lighting, tables, shelving specs and any other pertinent intellectual property, developed and refined by Medicine Man Denver.

We also have experience in supporting multiple facility layouts and deployments, including both existing and new buildings. We have worked through both deployments and have extensive knowledge within industrial building environments. Our documented designs and floor plans ensure your facility will operate at maximum efficiency from day one, avoiding the multitude of costly mistakes made by many cannabis startups.

We have just hired a full time interior design professional with a substantial commercial space planning background that will enable our team to become more valuable in that we can now provide CAD file design guidance.

### *Financial Modeling*

We assist clients with financial modeling and pro forma financial statement development which is a critical activity for every cannabis business irrespective of its age and size. For new enterprises, especially in the cannabis industry, the preparation of financial projections is integral to the business planning process.

Financial models are used to compile forecasts and budgets; to assess possible funding requirements; and to explore the likely financial consequences of alternative funding, marketing or operational strategies. They can also be used for business planning, raising finance, investment or funding appraisals, financial analysis, corporate planning etc. Used effectively, a financial model can help prevent major planning errors; identify or evaluate opportunities; attract external funding; provide strategic guidance; evaluate financial and development options; monitor progress etc.

### *New State Application Process Support Services (Template Support Based)*

Our primary objective is to help clients deliver a positive customer experience with the utmost attention to product, public, and patient safety. We provide education to our clients as to how to produce the highest quality products with the lowest cost of production, delivered to customers with great customer service on a consistent and safe basis.

Through our providing basic application support guidance elements, we support client's efforts in pursuit of state-issued operating license. Our team provides a cultivation and/or dispensary element (once known) as may be needed to demonstrate sufficiency within an application. Our proven application support experience has successfully distinguished our client's applications in this emerging industry.

We have experience working within both competitive and non-competitive application environments. We have navigated the application process in several states, including: Colorado, Nevada, Illinois, New York, Maryland, Hawaii, Pennsylvania and Puerto Rico. As each state handles the process differently, we bring a wealth of knowledge and experience in working through an application and believe in an "on the ground" approach – ensuring clients receive support when it matters most. As a result, our clients have successfully filed winning cultivation and dispensary applications across several states.

Once a client has secured your state-issued operating license, we will support their efforts to become fully operational through the licensing of our proprietary cultivation and dispensary methodologies on an 'as needed' basis. Our team of seasoned consultants helps applicants navigate the process of pursuing state licensure and becoming a successful cannabis operation.

This service offering is generally provided as an 'assembly needed' product wherein we provide basic guidance elements for a particular state's deployment initiative that can then be incorporated in to an application process.

### *Licensing Services, Existing or New State Based (Full Service)*

Through our licensing services, we support a client's efforts within a competitive or non-competitive state application process with the goal of securing a state-issued operating license. Once licensed, we help clients deploy state of the art facilities, train staff, implement standard operating procedures, and become operational.

Entities applying for medical and recreational operating licenses will have to demonstrate their ability to ensure patient, product, and public safety while also maximizing their productivity to meet the forthcoming demand with high-quality, consistent products. Our latest tests have increased the per light productivity to 3 pounds of dried, cured flower per 1,000w fixture – this is invaluable in states which impose limits on canopy size or plant counts, or in instances in which operators have a limited space to cultivate within. We treat cultivation like manufacturing with the underlying principal that consistent input should yield consistent output, and have developed a process to back this up.

Licensing services include the following support throughout the pre-application process:

- Real estate sufficiency reviews and planning
- Generate facility design plans that client design build team can utilize in the creation of architectural and construction plans
- Provide client with pro forma for financial modeling
- Provide client with a facility equipment list
- Provide client with organizational charts and job description information
- Provide client with a list of preferred third-party vendors for consideration
- Provide client with an application checklist once the final rules are published
- Provide client with narrative of our operating plans for use in demonstrating qualification for state licensure

Licensing services include the following support throughout the post-application process:

- Provide client with facility shop drawings (tables, racks, lighting systems, etc.)
- Provide client with detailed Standard Operating Procedures
- Provide client with further design and deployment support related to facility construction
- Provide client with on-site training within our Denver-based facilities
- Provide client with on-site training at their facilities once operational
- Provide on-going support for a period of five years including the ongoing dissemination of process improvements or adjustments to standard operating procedures

Clients who successfully achieve state licensure may also engage us for managed facility support. This offering provides a turn-key solution for new operators, inclusive of support with pursuit of licensure, design and deployment of their facility, and ongoing management of the facility for a defined period of time.

#### *Three-A-Light Publication (Home Version)*

Pono is the holder of all intellectual property rights relating to the cannabis cultivation of full scale commercial grow operations utilized and proposed to be utilized by our current and future clients. No patents have been filed to protect the various methods and expertise utilized for these commercial grows because of the federal prohibition on cannabis.

“Three-a-light” is a tutorial for how to grow cannabis plants for the individual grower growing for his own benefit or caregiver growing for their patients in a limited way. The book is currently offered on Amazon at a price of \$500 per copy, the highest price for a book offered by Amazon. To date, approximately 1,100 books have been sold.

There are key differences between growing cannabis indoors and outdoors. While outdoor crops can yield more, the quality of indoor cannabis cannot be matched. This book teaches the secrets of getting the greatest yield without sacrificing quality and includes a step-by-step marijuana growing guide from seed to finished flower. It provides a simple approach to a very painstaking and complex process. It contains illustrations on how to grow cannabis and covers the nine vital components of growing marijuana indoors in order to achieve the highest average yield per light.

We believe the sale of “Three-a-light” books advance the use of our cultivation techniques, use of our proprietary nutrients, and provides brand exposure as well as leads to new service provider relationships that over time will be significant.

#### *Three-A-Light Publication (Professional Version)*

It should be noted that our Three-A-Light Professional Version is only made available to licensed or operational clients utilizing full cultivation support (i.e. Cultivation MAX, licensing, etc.).

#### *Existing Cultivation and Dispensary Operation (Group 2)*

##### *Cultivation Max Services*

As the legal cannabis marketplace evolves and the price of products stabilizes, there is an increasing need to control the cost of production and maximize a cultivation facility’s performance. Through our Cultivation Max services, the Company optimizes existing cultivation operator’s existing facilities to improve yield, consistency, quality, and efficiency in order to maximize its full production potential. The service is designed to enable existing operators to become highly efficient cultivators, allowing them to continually compete in a highly competitive landscape.

Through the implementation of our proprietary cultivation methodology, facility and room design, plant and nutrient management the Company may significantly improve existing performance within a client’s facility. The Company understands the uniqueness of existing facilities and customizes the approach to each project to ensure mutually beneficial results. The Company earns revenue based on the delta of performance improvement beyond the baseline performance documented at the beginning of the engagement. The term of a Cultivation Max agreement as well as the percentage of revenue is determined on a per project basis.

As an example of this performance delta over existing indoor as well as greenhouse based performance, it is generally known that existing indoor cultivation practices are considered best practices when achieving two (2) pounds per light in terms of dried cured flower per harvest cycle or approximately one (1) gram per watt. This is based upon five (5) to six (6) harvest cycles per year. A greenhouse will likely mimic this level of performance but generally may achieve fewer harvests per year. According to a recent MJardin Study (as included in the ArcView 2015 Annual Industry Report), average yields in terms of grams per square foot of flower canopy range between 168 and 282 grams annually. Current performance for the Three-A-Light Professional cultivation practice generates approximately 700 grams per square foot of dried cured flower per square foot of flower space annually (based upon 5.5 harvests per year utilizing a thirty-two square (32) foot table supporting eight (8) plants that yields approximately nine (9) pounds per harvest or 5.5 times nine (9) pounds times 453 grams per pound divided by thirty-two (32) square feet or a total of approximately 700 grams per square foot per annual period) which represents a substantial competitive advantage to our clients.

This level of superior performance is based upon a proven cultivation practice that includes a very specific feeding and integrated pest management system that is hand managed and does not (at this time) have any reliance on automated technology since the overall operating cost per pound of dried cured flower more than offsets the use of additional labor. These results are based upon use of 1,000 watt double ended lamps that are substantially more efficient than this use of other lower operating cost lamps of an LED or other nature that can be three to four times more expensive from a capital deployment perspective.

### *Managed Facility Services*

As the Company has grown, the volume of requests for full facility management has increased. As a result, the Company has structured a service offering to include organizational setup and interim management of client's cultivation, processing, and dispensary facility(s). As part of the managed facilities services, the Company may provide the following:

1. Oversee the hiring and training of the primary facility General Manager. General Manager will oversee the hiring and training of market-based Cultivation Manager, Production Manager, and Dispensary Manager, as necessary, who may all train on-site in Colorado while client facilities are under construction.
2. Provide organizational charts and job descriptions to aid client management team in hiring within their local market.
3. If desired, embed a Senior Cultivation Team Member within the client's facility for a defined period of time, beginning at a time mutually determined between the Company and the Client. Upon completion of the service agreement, opportunity for full-time employment is typically made available to client.
4. If desired, embed a Senior Processing Team Member within the client's facility for a defined period of time, beginning at a time mutually determined between the Company and the Client. Upon completion of the service agreement, opportunity for full-time employment is typically made available to client.
5. If desired, embed a Senior Dispensary Team Member within the client's facility for a defined period of time, beginning at a time mutually determined between the Company and the Client. Upon completion of the service agreement, opportunity for full-time employment is typically made available to client.
6. All costs for the above services to be covered by the client including time and expense.

Revenue for managed services is derived on a fee basis for ongoing support and also incentivized by production metrics tied to overall facility performance. These services are typically provided through a custom assessment and bidding process.

### *Products (Group 3)*

#### *Success Nutrients*

SN was incorporated in Colorado on May 5, 2015. Since inception SN has been engaged in the manufacturing and wholesale and retail distribution of nine different plant nutrients for cannabis, each of which comes in three separate sizes and which has been primarily marketed to the cannabis industry, more specifically, cultivation experts and other growers in the cannabis industry in Colorado. Each of SN's nine product lines are sold in three separate sizes, with retail pricing ranging from \$25-\$30 for small packages up to a range of \$200-\$300 for large packages.

The development of SN's product line was the result of consolidation of all the micro and macro nutrients found to produce the most grams of cannabis flower per square foot while achieving the highest quality possible. Until January 2017, SN's operations were primarily directed towards in the cannabis industry in the state of Colorado. Subsequently, SN's products were successfully registered with the state agricultural departments for California, Oregon, Washington, Arizona and Michigan, as well as in Canada. Prior to obtaining this registration the SN products were only able to be purchased online. As a result of being registered, all SN products can now be displayed on retail shelves in those aforesaid states. SN will continue to pursue product registration in other states and countries prioritizing those locations that provide greater market size for its products.

The Success Nutrients brand provides one of the key underpinnings of the cultivation methodology and is essential to the overall Three a Light™ performance metric, which is discussed more fully below under "Business of Pono." With an investment of two years of research, development and intense testing, this product line was specifically formulated for the cannabis industry.

SN's goal is to revolutionize modern cannabis gardening as it is currently known with an emphasis on stronger plants, healthy flowers and an overall cleaner product. Generally, growers of cannabis have been able to generate approximately 1.5 lbs. per grow light. By using both the nutrients offered by SN, together with the process offered by Pono, results have more than doubled in some cases. While no assurances can be provided, we believe that this will add substantial growth to our existing cannabis consulting operation, especially as the cannabis industry continues to grow and expand as additional states approve the use and cultivation of medical and recreational marijuana. We believe that if we offer prospective new clients the opportunity to learn cultivation techniques that allow them to increase production over their competitors, our business will increase, which is one of the primary purposes of the Transactions. The combination of SN and Pono registration techniques have directly resulted in the creation of a new line of consulting services that improve the performance of current cultivations. We call this service "Cultivation Max." We have already signed several new clients for this service.

### *Three-A-Light Publication (Home Version)*

Pono was incorporated in the State of Colorado on February 16, 2015. It is the holder of all intellectual property rights relating to the cannabis cultivation of full scale commercial grow operations utilized and proposed to be utilized by our current and future clients. No patents have been filed to protect the various methods and expertise utilized for these commercial grows because of the federal prohibition on cannabis.

“Three-a-light” is a tutorial for how to grow cannabis plants for the individual grower growing for his own benefit or caregiver growing for their patients in a limited way. The book is currently offered on Amazon at a price of \$500 per copy, the highest price for a book offered by Amazon. To date, approximately 1,100 books have been sold. Pono currently generates approximately \$25,000 to \$40,000 a month in revenue (through February 2017) from the sale of these books and other related services.

There are key differences between growing cannabis indoors and outdoors. While outdoor crops can yield more, the quality of indoor cannabis cannot be matched. This book teaches the secrets of getting the greatest yield without sacrificing quality and includes a step-by-step marijuana growing guide from seed to finished flower. It provides a simple approach to a very painstaking and complex process. It contains illustrations on how to grow cannabis and covers the nine vital components of growing marijuana indoors in order to achieve the highest average yield per light.

We believe the sale of “Three-a-light” books advance the use of our cultivation techniques, use of our proprietary nutrients, and provides brand exposure as well as leads to new service provider relationships that over time will be significant.

### *Three-A-Light Publication (Professional Version)*

It should be noted that our Three-A-Light Professional Version is only made available to licensed or operational clients utilizing full cultivation support (Cultivation MAX).

## **Competitive and Client Base**

### **Competitive Advantage**

As we continue to grow, amassing additional experience and knowledge (similar to our recent substantial gains in as represented by Three-A-Light and Success Nutrients) we believe we will continue to enjoy a competitive advantage within the industry over any other business providing a group of service offerings similar to our own.

With our focus on the fulfillment of a brands warehouse concept, wherein we can commonly acquire, market, value, and cross promote various Cannabusiness enterprises we believe that over time we will be able to achieve a more economical cost of operations (public company) while delivering highest quality goods and services that generate strong shareholder returns in terms of our stock value in this nascent space.

As with our latest new product, Cultivation MAX we are now working with existing underperforming cultivation facility ownership groups wherein we provide access to our advanced knowledge as well as proprietary nutrients wherein we are only compensated on the delta achieved over their existing performance (generally less than 1.5 pounds a light or 350 grams of dried cured flower per square foot of flower canopy) while also guaranteeing through payment reduction that their existing cost per pound to cultivate will not increase.

Unlike most ‘consultants’ in this industry, we have proven that we do not know it all and as we continue to be ready to learn from others (through acquisition and or cooperation), we believe that ability in and of itself will allow us to continue to expand our client base and revenues substantially.

## General Client Summary

Medicine Man Technologies has been actively involved in the state application process on behalf of our clients. To date we have actively participated in an application process in the following states: Colorado, California, Florida, Illinois, Nevada, New York, Maryland, Hawaii, Oregon, Pennsylvania and Puerto Rico. As with most consultants, we have won and lost in pursuit of a license application process. To date we have assisted clients in securing the following licenses or have active clients as follows:

- Four (CUP authorized or in process status) California Cultivation Licenses
- One Colorado cultivation license
- Three Colorado dispensary licenses (Denver, Aurora, Thornton)
- Two Illinois cultivation licenses
- Four Illinois dispensary licenses
- Two Nevada cultivation licenses
- Two Nevada Cultivation MAX Client Licenses
- One Maryland processing license
- One Maryland cultivation license
- Three Maryland dispensary licenses
- One Hawaii vertically integrated license noting the applicant was top scored in Kauai and removed for investor background check violations
- One Oregon Tier II Cultivation License and One Oregon Medical Cultivation License (outdoor)
- We have one active cultivation client and one pending Puerto Rico cultivation application

We have already begun to generate new business opportunities in Michigan, Ohio, Florida, and Arkansas and have more recently initiated Cultivation MAX support services for two larger Nevada clients (500 light and 400 light) which, over time should generate significant income for the Company.

Related Parties – Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company. The Company disclose related party transactions that are outside of normal compensatory agreements, such as salaries or director fees. The Company has related party transactions with the following individuals / companies:

- *Super Farm LLC* – Joshua Haupt, Chief Cultivation Officer of the Company, has a 20% ownership
- *De Best Inc* – Joshua Haupt, Chief Cultivation Officer of the Company, has a 20% ownership
- *Medicine Man Denver* – Andy Williams, Director of the Company, has a 38% ownership
- *Josh Haupt* – Chief Cultivation Officer of the Company

### 1. Liquidity and Capital Resources :

Cash Flows – During the quarters ending June 30, 2017 and 2016, the Company primarily utilized cash and cash equivalents and profits from operations to fund its operations.

Cash and cash equivalents are carried at cost and represent cash on hand, deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date. The Company had \$200,600 and \$351,524 classified as cash and cash equivalents as of June 30, 2017 and December 31, 2016, respectively.

### 2. Critical Accounting Policies and Estimates :

Basis of Presentation: These accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial statements.

*Fair Value Measurements:* Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.

Our financial instruments include cash, accounts receivable, note receivable, accounts payables and tenant deposits. The carrying values of these financial instruments approximate their fair value due to their short maturities. The carrying amount of our debt approximates fair value because the interest rates on these instruments approximate the interest rate on debt with similar terms available to us. Our derivative liability was adjusted to fair market value at the end of each reporting period, using Level 3 inputs.

*Use of Estimates:* The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.

*Accounts receivable:* The Company extends unsecured credit to its customers in the ordinary course of business. Accounts receivable related to licensing revenues are recorded at the time the milestone result in the funds being due has been achieved, services are delivered and payment is reasonably assured. Licensing revenues are generally collected from 30 to 60 days after the invoice is sent. As of June 30, 2017, and December 31, 2016, the Company had accounts receivable of \$231,399 and \$25,000, respectively. The company wrote off \$0 of its accounts receivable in the current quarter. Allowance for doubtful accounts is currently zero as all receivables are less than 60 days old. The company will continue to evaluate the need for recognizing an additional allowance in the future.

*AFS Securities:* Investments available for sale is comprised of publicly traded stock purchased as an investment. The Company considers the securities to be liquid and convertible to cash in under a year. The Company has the ability and intent to liquidate any security that the Company holds to fund operations over the next twelve months, if necessary, and as such has classified all its marketable securities as short-term. Our investment securities at June 30, 2017 consist of available-for-sale instruments which include \$17,701 of equity in publicly traded companies. All our available-for-sale securities are Level 2 due to limited trading volume. Realized gains and losses on these securities will be included in “other income (expense)” in the consolidated statements of income using the specific identification method. Unrealized gains and losses, net of tax, on available-for-sale securities are recorded in accumulated other comprehensive income (accumulated OCT).

*Short term note receivable:* Notes receivable is comprised of a \$250,000 loan with \$28,893 of accrued interest for a total loan value of \$278,893 issued to the organization that owns Funk Sack, Inc. This loan was extended with the option of negotiating an agreement to acquire the entirety of the company through a stock swap. However, in the fourth quarter of 2016 the Company determined that it would not complete the acquisition of the company and instead will hold the investment and it will be repaid. The loan was issued May 6, 2016 and is due to be repaid November 1, 2017. As the note is still current and the Funk Sacks organization is continuing to operate and grow this note is considered to be fully collectable.

*Other assets:* Other assets at June 30, 2017 and December 31, 2016 were \$50,006 and \$27,479, respectively and as of June 30, 2017 included \$25,506 in prepaid registrations fees for major cannabis events the Company is sponsoring and advertising costs and \$24,500 in two security deposits.

*Accounts payable:* Accounts payable at June 30, 2017 and December 31, 2016 was \$32,328 and \$0, respectively.

*Other liabilities:* Other liabilities at June 30, 2017 and December 31, 2016 were \$10,713 and \$175, respectively. At June 30, 2017, this was comprised of \$10,352 in accrued expense.

*Fair Value of Financial Instruments:* The carrying amounts of cash and current assets and liabilities approximate fair value because of the short-term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates. Available for sale securities are recorded at current market value as of the date of this report.



*Revenue recognition and related allowances:* Revenue from licensing and consulting services is recognized when the obligations to the client are fulfilled which is determined when milestones in the contract are achieved. Revenue from seminar fees is related to one-day seminars and is recognized as earned at the completion of the seminar. Revenue from product sales either being nutrients or book sales are recognized when the goods is transferred. All revenue is measured at fair value.

*Costs of Services Sold* – Costs of services sold are comprised of direct salaries and related expenses incurred while supporting the implementation of licensing agreements and related services.

*General & Administrative Expenses* – General and administrative expense are comprised of all expenses not linked to the production or advertising of the Company's services.

*Advertising and Marketing Costs:* Advertising and marketing costs are expensed as incurred and were \$89,509 and \$21,672 during the six months ended June 30, 2017 and 2016, respectively.

*Stock based compensation:* The Company accounts for share-based payments pursuant to ASC 718, "Stock Compensation" and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock and restricted stock awards using the Black-Scholes option pricing model.

Stock compensation expense for stock options is recognized over the vesting period of the award or expensed immediately under ASC 718 and EITF 96-18 when stock or options are awarded for previous or current service without further recourse. The Company issued stock options to contractors and external companies that had been providing services to the Company upon their termination of services. Under ASC 718 and EITF 96-18 these options were recognized as expense in the period issued because they were given as a form of payment for services already rendered with no recourse.

Share based expense paid to through direct stock grants is expensed as occurred. Since the Company's stock has become publicly traded, the value is determined based on the number of shares issued and the trading value of the stock on the date of the transaction. Prior to the Company's stock being traded the Company used the most recent valuation. The Company recognized \$4,480,318 in expenses for stock based compensation to employees and consultants during the six months ended June 30, 2017.

*Income taxes:* The Company has adopted SFAS No. 109 – "Accounting for Income Taxes". ASC Topic 740 requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

*Management fee contracts:* In February 2017, the Company entered into a Merger Agreement with Pono Publications Ltd. ("Pono"), as well as a Share Exchange Agreement with Success Nutrients, Inc. ("SN"), each a Colorado corporation, in order to facilitate the acquisition of both of these entities. The ratification of the acquisition of these companies requires the approval of the holders of a majority of the Company's shareholders, which was submitted for such approval at the Company's annual shareholder meeting held on May 2017. The relevant agreements provide that the effective date for accounting purposes would be April 1, 2017. Success Nutrients became a wholly owned subsidiary of Medicine Man Technologies, Inc. and the business conducted by Pono was incorporated into a newly formed wholly owned subsidiary, Medicine Man Consulting, Inc., which is also where the Company will continue to conduct its consulting service business.

In March 2017, the Company integrated Pono Publications and Success Nutrients into its operations including a lease for approximately 10,000 square feet of space located at 6660 East 47th Street, Denver, CO 80216. This integration also included four (4) full time team members as well as several independent contractors. From April 1, 2017 to June 30, 2017 the Company has agreed to manage the acquirees through a management fee agreement whereby all cash collected was recognized as other income and all cash expenses were direct costs of the project. As of June 30, 2017, the management contract resulted in cash collections of approximately \$100,000 and cash expenditures of approximately \$170,000 resulting in a net loss of \$70,257 which was presented on a net basis as a loss in the other income portion of our income statement. As of April 1, 2017 the Company's consolidated financial statements included these two entity's.

### 3. Recent Accounting Pronouncements

*FASB ASU 2017-01 "Clarifying the Definition of a Business (Topic 805)"* – In January 2017, the FASB issued 2017-1. The new guidance that changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. The guidance requires an entity to evaluate if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of transferred assets and activities is not a business. The guidance also requires a business to include at least one substantive process and narrows the definition of outputs by more closely aligning it with how outputs are described in ASC 606. The ASU is effective for annual reporting periods beginning after December 15, 2017, and for interim periods within those years. Adoption of this ASU is not expected to have a significant impact on our consolidated results of operations, cash flows and financial position.

*FASB ASU 2016-15 "Statement of Cash Flows (Topic 230)"* – In August 2016, the FASB issued 2016-15. Stakeholders indicated that there is a diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. Adoption of this ASU will not have a significant impact on our statement of cash flows.

*FASB ASU 2016-11 "Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815)"* – In May 2016, the FASB issued 2016-11, which clarifies guidance on assessing whether an entity is a principal or an agent in a revenue transaction. This conclusion impacts whether an entity reports revenue on a gross or net basis. This ASU is effective for annual reporting periods beginning after December 15, 2017, with the option to adopt as early as December 15, 2016. We are currently assessing the impact of adoption of this ASU on our consolidated results of operations, cash flows and financial position.

*FASB ASU 2015-11 "Inventory (Topic 330): Simplifying the Measurement of Inventory," or ASU 2015-11* - In July 2015, the FASB issued ASU 2015-11, which requires an entity to measure in scope inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments apply to inventory that is measured using first-in, first-out (FIFO) or average cost. This ASU is effective for interim and annual reporting periods beginning after December 15, 2016, with the option to early adopt as of the beginning of an annual or interim period. Adopting this ASU did not have a significant impact on our financial position, results of operations and cash flows.

### 4. Stockholders' Equity :

The Company's initial authorized stock at inception was 1,000,000 common shares, par value \$0.001 per share. In 2016 the company subsequently amended its Articles of Incorporation to increase its authorized shares to 90,000,000 Common Shares, par value \$0.001 per share and 10,000,000 preferred shares, par value \$0.001 per share.

During the time in which the Company was establishing its operations it issued 4,199,000 shares of Common Stock to various individuals as founders for prior services completed which was valued at par value, resulting in the Company booking stock based expense of \$4,199.

During the time in which the Company was establishing its operations it issued 5,331,000 shares of Common Stock to various individuals for a license agreement valued at par value resulting in the Company recognizing a purchased asset of \$5,331.

Commencing in November 2014, the Company commenced a private offering of its Common Stock at an offering price of \$1.00 per share. At December 31, 2014, it had accepted subscription from 26 investors and received net proceeds of \$260,000 therefrom.

In December 2014, the Company issued 50,000 shares of its Common Stock for legal fees and recognized an expense for this issuance of \$50,000 based upon the prior sale in November 2014 of its Common Stock.

On March 17, 2015, 10,000 shares of Common Stock were sold to one investor as part of the private offering commencing in November 2014 in exchange for \$10,000 cash.

During the second quarter of 2015, the Company issued 50,000 shares of Common Stock to an individual in consideration for their services rendered in support of the Company resulting in the Company recognizing compensation expense of \$50,000 based upon a per share price of \$1.00 per share realized in the most recent private offering.

On July 1, 2015, the Company issued 72,500 shares of Common Stock to four different individuals in consideration for their services rendered in support of the Company, resulting in recognizing compensation expense of \$29,725 based upon an independent valuation determining the value of shares at \$0.41 per share.

At December 31, 2015, the Company had 9,972,500 shares outstanding.

On January 4, 2016, the Company issued 120,000 shares of Common Stock to various individuals in consideration of their services rendered in support of the Company resulting in recognizing compensation expense of \$49,200 based upon an independent valuation determining the value of shares at \$0.41 per share.

During the three months ended March 31, 2017, the Company issued 145,587 shares of Common Stock upon conversion of convertible notes in the aggregate amount of \$254,777.

On June 3, 2017, the Company issued 1,400,000 shares of Common Stock to various individuals in consideration of their services rendered in support of the Company resulting in recognizing compensation expense of \$2,380,000 based upon the closing stock price on June 2, 2017 at \$1.70 per share.

On June 3, 2017, the Company issued 7,000,000 shares of Common Stock in consideration for the acquisition of Success Nutrients and Pono Publications.

On June 3, 2017, the Company issued 2,000,000 warrants to purchase Common Stock to three individuals. See Note 15 for further explanation.

During the three months ended June 30, 2017, the Company issued 44,151 shares of Common Stock upon conversion of convertible notes in the aggregate amount of \$60,000.

At June 30, 2017, the Company had 18,992,238 common shares outstanding.

#### 5. Property and Equipment :

Property and equipment are recorded at cost, net of accumulated depreciation and are comprised of the following:

	<b>June 30, 2017</b>	<b>December 31, 2016</b>
Furniture & Fixtures	\$ 82,415	\$ 11,526
Marketing Display	36,900	42,681
Vehicles	6,000	-
Office Equipment	74,996	10,838
	<u>\$ 200,311</u>	<u>\$ 65,045</u>
Less: Accumulated depreciation	(46,278)	(22,919)
	<u>\$ 154,033</u>	<u>\$ 42,126</u>

Depreciation on equipment is provided on a straight-line basis over its expected useful lives at the following annual rates.

Furniture & Fixtures	3 years
Marketing Display	3 years
Vehicles	3 years
Office Equipment	3 years

Depreciation expense for the six-month periods ending June 30, 2017 and 2016 was \$23,576 and \$8,266 respectively.

## 6. Intangible Asset

On May 1, 2014, the Company entered into a non-exclusive Technology License Agreement with Futurevision, Inc., f/k/a Medicine Man Production Corporation, a Colorado corporation, dba Medicine Man Denver (“Medicine Man Denver”), a company owned and controlled by affiliates of the Company, whereby Medicine Man Denver granted a license to use all of their proprietary processes they have developed, implemented and practiced at its cannabis facilities relating to the commercial growth, cultivation, marketing and distribution of medical marijuana and recreational marijuana pursuant to relevant state laws and the right to use and to license such information, including trade secrets, skills and experience (present and future). As payment for the license rights the Company issued Medicine Man Denver (or its designees) 5,331,000 shares of the Company’s common stock. The Company accounted for this license in accordance with ASC 350-30-30 “Intangibles – Goodwill and Other by recognizing the fair value of the amount paid by the company for the asset at the time of purchase. Since the Company has a limited operating history, management determined to use par value as the value recognized for the transaction. Since the term of the initial license agreement is ten (10) years, the cost of the asset will be recognized on a straight-line basis over the life of the agreement. In addition, each period the Company will evaluate the intangible asset for impairment. As of December 31, 2014, no impairment was deemed necessary.

During 2016, the Company attained two intangible assets, Product Agreement & Registration and a Trade Secret. These two intangible assets were acquired due to the result of the acquisition of Success and Pono on June 30, 2017. Refer to the Note 9 for further explanation of the purchase price accounting. The Company’s procurement of product registration during the year was within five states and Canada. The Company’s product was registered in California, Oregon, Colorado, Michigan, Arizona, Washington and all of Canada. The registration allows the Company to sell their product within the confines of that region. The registration fees capitalized are the initial costs to obtain the license. The licenses have nominal annual renewal costs. These subscriptions are amortized over a 15-year period.

During 2016, the Company incurred an intangible asset due to the development of the products nutrient recipe. The nutrient recipe development was a onetime fee, paid to the Company’s developer. The intellectual property is amortized over a 15-year economic life of the asset. The economic life of the asset is shorter than the indefinite life considered the legal life of the assets so 15 years is deemed the economic life of the asset.

Amortization expense for the periods ending June 30, 2017 and 2016 was \$1,463 and \$266, respectively.

	<b>June 30, 2017</b>	<b>December 31, 2016</b>
License Agreement	\$ 5,300	\$ 5,300
Product License and Registration	38,124	–
Trade Secret - IP	32,500	–
	<u>\$ 75,924</u>	<u>\$ 5,300</u>
Less: accumulated amortization	(3,055)	(1,592)
	<u>\$ 72,869</u>	<u>\$ 3,708</u>

## 7. Convertible Notes and Derivative Liability:

At December 31, 2016 the Company had raised \$810,000 through a private placement of promissory convertible notes with certain accredited investors, bearing interest at 12%, with interest and principal due January 1, 2019. During the quarter ended June 30, 2017 the Company did not raise any additional capital with the same terms. In the period ended June 30, 2017 the Company converted \$60,000 of promissory convertible notes with certain accredited investors, bearing interest at 12%, with interest and principal due January 1, 2019, into 44,151 shares of common stock.

Upon issuance, each of the notes is immediately convertible at the noteholders election into the Company's common stock at \$1.75 per share or 90% of the VWAP of the five days following the notice of conversion, whichever is lower. Since the conversion rate can be tied to an underlying item, the notes are considered to be a derivative that is recorded as a liability at fair value and adjusted to fair value at the conclusion of each reporting period. The underlying assumptions used in the Black Scholes model to determine the fair value of the derivative liability were based on the individual date the notes were closed and were the following:

	Upon issuance	June 30, 2017
Current stock price	\$ 1.66 to \$4.35	\$1.39
Risk-free interest rate	.67%	1.38%
Expected dividend yield	0	0
Expected term (in years)	2.39 to 2.09	2.39 to 2.09
Expected volatility	85% to 114%	123%

Changes in the derivative liability were as follows:

January 1, 2017	\$294,002
Gain on derivative liability	(131,383)
Conversion of notes - APIC	(139,602)
June 30, 2017	<u>\$23,017</u>

#### 8. Related Party Transactions:

As of June 30, 2017, the Company has three related parties, Medicine Man Denver, De Best Inc. and Super Farm LLC. One of the Officers of the Company, Joshua Haupt, currently owns 20% of both De Best and Super Farm. During 2017, the Company had net sales from Super Farm LLC totaling \$61,251 and \$21,553 sales from De Best Inc. The Company give's a larger discount to related parties than non-related parties. The gross profit margin for related parties was 49% at June 30, 2017. As of June 30, 2017, the Company had accounts receivable balance with Super Farm LLC totaling \$13,561 and \$3,660 accounts receivable from De Best Inc. During 2017, the Company had cost of sales associated with Super Farm LLC totaling \$12,698 and \$4,720 from De Best Inc. Additionally, one of the Directors of the Company, Andy Williams, currently owns 38% of Medicine Man Denver. During 2017, the Company had net sales from Medicine Man Denver totaling \$40,140, accounts receivable balance of \$7,073 and cost of sales totaling \$8,618.

#### 9. Goodwill and Acquisition accounting:

On June 3, 2017, the Company issued an aggregate of 7,000,000 shares of its common stock for 100% ownership of both Success Nutrients and Pono Publications. The Company utilized purchase price accounting stating that net book value approximates fair market value of the assets acquired. The purchase price accounting resulted in the Company valuing the investment as \$6,301,080 of Goodwill. The ASC at 350-20-35-3A directs that "An entity may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that the fair value of a reporting unit is less than its carrying amount, including goodwill". During 2017, the Company obtained an independent valuation of the Company at 6.2.17. The fair market value at 6.2.17 of the Company was valued at \$17,031,748, thus creating a fair market value greater than the carrying value of Goodwill. The ASC at 350-20-35-3D directs that "If an entity determines that it is not more likely that the fair value of a reporting unit is less than its carrying amount, then Goodwill impairment is unnecessary." Additionally, the valuation that was obtained for the Company at 6.2.17 valued the Company's per share value of Common Stock at \$.93. This price was used because of the large block of stock given creates a blockage discount since it can't all be sold at market prices immediately. The valuation was used to value the stock instead of the \$1.70 market price due to the large amount of stock involved.

**Pono and Success Balance Sheet**

	<u>Book Value</u>	<u>Fair Value</u>		<u>Book Value</u>	<u>Fair Value</u>
<i>Assets</i>			<i>Liabilities</i>		
Accounts receivable	86,659	86,659	Accounts payable	3,268	3,268
Inventory	109,174	109,174	Note payable	58,280	58,280
PPE	16,922	16,922	Other liabilities	11,352	11,352
Intangibles	69,065	69,065		<b>72,900</b>	<b>72,900</b>
	<b>281,820</b>	<b>281,820</b>			
Purchase Price (7,000,000 *.93)		6,510,000			
Less: BV of Assets		(281,820)			
Add: BV of Liabilities		72,900			
<b>Goodwill</b>		<b>6,301,080</b>			

**10. Inventory:**

As of June 30, 2017, and December 31, 2016, respectively, the Company had \$109,174 and \$0 of finished goods inventory. The Company only has finished goods within inventory because it does not produce any of its products. All inventory is produced by a third party. The inventory valuation method that the Company uses is the FIFO method. During 2017 and 2016, the company had \$0 obsolescence within their inventory.

**11. Note Payable:**

As of June 30, 2017, and December 31, 2016, the Company had a note payable balance of \$58,280 and \$0, respectively. The note payable is a balance that is due to an officer of the Company, Joshua Haupt.

**12. Net Income (Loss) per Share**

In accordance with ASC Topic 280 – “Earnings Per Share”, the basic earnings per common share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding. Diluted earnings per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company's quarterly earnings for the period ended June 30, 2017 and 2016 basic and diluted earnings/(loss) per share \$(0.22) and \$(0.02), respectively.

**13. Commitments and Concentrations :**

Office Lease – Denver, Colorado – The Company entered into a lease for office space at 4880 Havana Street, Suite 200, Denver, Colorado 80239. The lease period started March 1, 2017 and will terminate February 29, 2020, resulting in the following future commitments:

2017 fiscal year	\$ 95,947
2018 fiscal year	154,174
2019 fiscal year	171,000
2020 fiscal year	29,000

Office Lease – Denver, Colorado – The Company entered into a lease for office space at 6660 E. 47<sup>th</sup> Ave Drive, Denver, Colorado 80216. The lease commitment is split between both Success Nutrients and Pono Publications. The lease period started December 1, 2016 and will terminate November 30, 2020, resulting in the following future commitments:

2017 fiscal year	\$	115,328
2018 fiscal year		118,528
2019 fiscal year		121,728
2020 fiscal year		124,928

**14. Tax Provision:**

The Company had no tax provisions as of June 30, 2017 and December 31, 2016. The company had a net loss in the quarter ending June 30, 2017 and the deferred tax asset has a full valuation against it.

**15. Warrants:**

The Company issued one round of warrants related to various equity transactions that was approved by the Board on June 3, 2017 and issued on June 19, 2017. Since the terms weren't established until June 19, 2017, these were valued on this date per the signed agreements and issuance on June 19, 2017. The Company accounts for its warrants issued in accordance with the US GAAP accounting guidance under ASC 480. We estimated the fair value of these warrants at the respective balance sheet dates using the Black-Scholes option pricing model as described in the stock-based compensation section above, based on the estimated market value of the underlying common stock at the valuation measurement date of \$1.50, the remaining contractual term of the warrant of 2.5 years, risk-free interest rate of 1.38% and expected volatility of the price of the underlying common stock of 126%. There is a moderate degree of subjectivity involved when using option pricing models to estimate the warrants and the assumptions used in the Black Scholes option-pricing model are moderately judgmental.

	<u>Number of shares</u>	<u>Exercise Price</u>
Balance as of March 31, 2017	–	–
Warrants issued	2,000,000	\$ 1.445
Settlements	–	–
Balance as of June 30, 2017	<u>2,000,000</u>	

During the six months ended June 30, 2017, the Company issued 2,000,000 common stock purchase warrants to three employees of the Company with an exercise price of \$1.445 per share for a period of time expiring on December 31, 2019. As of June 30, 2017, none of the warrants were exercised. Stock-based compensation expense recognized for warrants during the six-month period ended June 30, 2017 was \$2,100,318.

**16. Subsequent event:**

Effective July 21, 2017, the Company consummated the acquisition of Denver Consulting Group LLC, a Colorado limited liability company (“DCG”). The Company issued an aggregate of 2,258,065 shares of its common stock to the DCG members in exchange for 100% of their issued and outstanding member interests, valued at \$3.5 million based upon the closing price of the Company’s Common Stock on the date the relevant Term Sheet was executed. As a result, DCG is now a wholly owned subsidiary of the Company. The transaction with DCG did not result in a change in the Company’s current management.

As a part of this acquisition, the Company absorbed four full-time DCG team members on a contingent to hire basis (90 day).

The Company entered into final negotiations with a Canadian company for exclusive representation of several of the Company’s goods and services as noted in Item 2 of this report wherein we would also be jointly developing a new product and service offering associated with lighting technology and deployment.

## **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion should be read in conjunction with our consolidated financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward looking statements in the following discussion and elsewhere in this report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward looking statements made by, or on our behalf. We disclaim any obligation to update forward looking statements.*

### **Overview**

We were incorporated on March 20, 2014, in the State of Nevada. On May 1, 2014, we entered into an exclusive Technology License Agreement with Medicine Man Denver, Inc., f/k/a Medicine Man Production Corporation, a Colorado corporation ("Medicine Man Denver") whereby Medicine Man Denver granted us a license to use all of their proprietary processes they have developed, implemented and practiced at its cannabis facilities relating to the commercial growth, cultivation, marketing and distribution of medical marijuana and recreational marijuana pursuant to relevant state laws and the right to use and to license such information, including trade secrets, skills and experience (present and future) (the "Medicine Man Denver License Agreement").

We commenced our business on May 1, 2014 and currently generate revenues derived from licensing agreements with cannabis related entities, as well as sponsoring seminars offered to the cannabis industry and other business endeavors related to our core competencies. As of the date of this report we have or have had 45 fee generating clients in 14 different states.

We are a cannabis consulting company providing services related to cost efficient cannabis cultivation technologies focusing on quality as well as safety, retail operations related to the delivery of cannabis related products, and other related business lines as described in our operating strategic vision outlines below.

We have never been subject to any bankruptcy proceeding. Our executive offices are located at 4880 Havana Street, Suite 201 South , Denver, Colorado 80239, telephone (303) 371-0387 . Our website address is [www.medicinemantechologies.com](http://www.medicinemantechologies.com).

### **RESULTS OF OPERATIONS**

#### *Results of Operations for the three months ended June 30, 2017 and 2016*

During the three months ended June 30, 2017, our second quarter we generated revenues of \$882,353, including consulting/licensing fees of \$530,195, product sales of \$352,158 as compared with the three months ended June 30, 2016, our comparative second quarter where we generated revenues of \$149,766, all of which were related to consulting/licensing services. This resulted in an increase in our consulting/licensing revenues of 254% or \$380,429 noting the balance of this increase was related to Success Nutrient sales which were not present in the same quarter one year earlier. Overall revenue increased during this three-month period over that of the prior year by 489% of \$732,587.

Cost of services, consisting of expense related to delivery of services and product procurement, was \$272,001 during the three months ended June 30, 2017, compared to \$44,177 during the comparable period in 2016, this increase was largely driven by the addition of product procurement expenses and increases in wages for the period. Operating expenses during the three months ended June 30, 2017, were \$5,172,869, including stock compensation expense of \$4,480,318, one-time acquisition costs of \$98,710, and general and administrative expense of \$593,850, compared to general and administrative expenses of \$207,059 incurred during the three months ended June 30, 2016, an increase of \$4,965,801. Increased operating expenses during this three-month period were primarily attributable to stock compensation and one-time acquisition expenses totaling \$4,579,019 as well as the cost increase of additional staff needed to service our expanding client base as reflected in our operating expense category.



As a result, we generated a net loss of \$4,494,435 during the three months ended June 30, 2017 (approximately (\$0.23) per share), compared to net loss of \$101,470 during the three months ended June 30, 2016. This net loss was primarily attributable to stock compensation and one-time acquisition expenses totaling \$4,579,019 which exceeds the total of net losses during this period.

The Company notes that during the first quarter of FY 2016 we only had three full-time and two part-time employees whereas in the second quarter of FY 2017 we had thirteen full-time and two part-time employees.

*Results of Operations for the six months ended June 30, 2017 and 2016*

During the six months ended June 30, 2017, we generated revenues of \$1,423,489, including consulting/licensing fees of \$1,067,109, product sales of \$352,158 with the balance of fees arising from our participation in cannabis seminars. In the six months ended June 30, 2016 revenue generated was \$349,381 with \$337,221 generated through consulting/licensing fees. From June 30, 2017 to June 30, 2016 we had an 307% increase revenue. This increase was due to the acquisition of Pono and Success, growth in our service model and growth within our client base.

Cost of services, consisting of expense related to delivery of services and product procurement, was \$437,160 during the six months ended June 30, 2017, compared to \$181,618 during the comparable period in 2016, this increase was largely driven by the addition of product procurement expenses and increases in wages for the period. Operating expenses during the six months ended June 30, 2017, were \$5,401,754, including stock compensation expense of \$4,480,318, general and administrative expense of \$435,296, compared to general and administrative expenses of \$312,217 incurred during the six months ended June 30, 2016, an increase of \$123,079. Increased operating expenses included additional cost incurred related to professional fees of \$332,184 incurred during the period, as well as \$89,509 in advertising expense incurred during the six months ended June 30, 2017, compared to advertising expenses of \$21,672 during the corresponding period in 2016. During the six months ended June 30, 2017, the Company incurred \$98,701 in one-time acquisition costs related to the Pono and Success acquisition.

The Company notes that during the first quarter of FY 2016 we only had three full-time and two part-time employees whereas in the second quarter of FY 2017 we had thirteen full-time and two part-time employees.

As a result, we generated net loss of \$(4,383,271) during the six months ended June 30, 2017 (approximately (\$0.22) per share), compared to net loss of \$(219,118) during the six months ended June 30, 2016. Of this net loss, we note that \$4,480,318 was related to extraordinary one-time costs related to stock compensation.

## **LIQUIDITY AND CAPITAL RESOURCES**

At June 30, 2017, we had \$200,600 in cash on hand.

Net cash used by operating activities was \$347,617 during the six-month period ended June 30, 2017, compared to cash used from operating activities of \$224,534 for the similar period in 2016, an increase of \$123,083. We anticipate we will continue to generate negative cash flow from operations until we complete the DCG acquisition.

Between November 2014 and March 2016, we undertook a private offering of our Common Stock wherein we sold 270,000 shares of our Common Stock for gross proceeds of \$270,000 (\$1.00 per share) to 4 non-accredited and 23 "accredited" investors, as that term is defined under the Securities Act of 1933.

From October 2016 through February 2017, we engaged in a private offering of convertible notes to 11 accredited investors (as that term is defined under Rule 501, Regulation D of the Securities Act of 1933, as amended). These loans provide for a fixed or VW AP conversion option, bear an annual interest rate of 12% (simple), with interest paid quarterly and mature on December 31, 2018. We issued notes totaling \$989,777. As of the date of this Report, Convertible Notes aggregating \$254,777 were converted to 145,587 shares of our Common Stock. These conversions were computed at both the floor value of \$1.75 as well as at a VWAP value as allowable under the terms of the conversion rights. See "Notes to Financial Statements."

As we continue to focus on expanding its branding warehouse concept, it will begin to require capital beyond its ability to support through normal cash flow sources. Over time these investments will begin to require less capital and be spread out over an ever-increasing corporate structure integrating various acquisitions as wholly owned subsidiary operations, all supporting a common brand and marketing strategy. Additionally, our ability to evolve into a low-cost public company entity will generate even better value to our shareholders as we are eliminating duplication of all the various related costs and services

We are currently in process of undertaking an effort to raise additional capital through the sale of our common stock. It is expected, though not assured, that this additional cash infusion will provide meet the cash requirements of the company until it will again start generating positive cash flow for its operations. However, if we are unable to secure this financing or generate profits from our operations or elect to expand our operations or otherwise require additional capital, we have no agreement with any third party to provide us the same and there can be no assurances that we will be able to raise any capital, either debt or equity on commercially reasonable terms, or at all. If we require additional capital and are unable to raise the same, it could have a material negative impact on our results of operations.

### ***Inflation***

Although our operations are influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the six-month period ended June 30, 2017.

### ***Off-Balance Sheet Arrangements***

We had no off-balance sheet arrangements as of June 30, 2017 and December 31, 2016.

### ***Critical Accounting Estimates***

Our financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the condensed financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended December 31, 2016 in the Critical Accounting Policies section of Management's Discussion and Analysis of Financial Condition and Results of Operations.

### ***Item 3. Quantitative and Qualitative Disclosures about Market Risk***

Not applicable

**Item 4. Controls and Procedures****Evaluation of Disclosure Controls and Procedures**

As required by Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we have carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2017. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer. Based on this evaluation, our CEO and CFO have concluded that our disclosure controls and procedures were effective as of June 30, 2017.

**Changes in Internal Control over Financial Reporting**

There have been no changes in our internal control over financial reporting during the last quarterly period covered by this report that have materially affected, or are reasonably likely to affect, our internal control over financial reporting.

## PART II — OTHER INFORMATION

### Item 1. *Legal Proceedings.*

We are not a party to any legal proceeding that we believe will have a material adverse effect upon its business or financial position, nor has any such action been threatened against us.

### Item 1A. *Risk Factors*

As a smaller reporting company, we are not required to provide the information required by this Item.

### Item 2. *Unregistered Sales of Equity Securities and Use of Proceeds*

During the six months ended June 30, 2017, we issued 189,738 shares of Common Stock upon conversion of convertible notes which reduced our debt in the aggregate amount of \$314,777. We used the funds received from the issuance of these convertible notes for working capital. We relied upon the exemption from registration provided by Regulation D to issue these shares.

### Item 3. *Defaults upon Senior Securities*

None.

### Item 4. *Mine Safety Disclosures*

Not applicable.

### Item 5. *Other Information*

None.

### Item 6. *Exhibits*

- 31.1 [Rule 13a-14\(a\)/15d-14\(a\) Certification of Chief Executive Officer](#)
- 31.2 [Rule 13a-14\(a\)/15d-14\(a\) Certification of Chief Financial Officer](#)
- 32 [Chief Executive Officer and Chief Financial Officer Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](#)
- 99.1 [Press Release dated August 17, 2017 titled "Medicine Man Technologies Reports Second Quarter 2017 Results"](#)

101.INS XBRL Instance Document\*  
101.SCH XBRL Schema Document\*  
101.CAL XBRL Calculation Linkbase Document\*  
101.DEF XBRL Definition Linkbase Document\*  
101.LAB XBRL Label Linkbase Document\*  
101.PRE XBRL Presentation Linkbase Document\*

\* Pursuant to Rule 406T of Regulation S-T, these interactive data files are not deemed filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act or Section 18 of the Securities Exchange Act and otherwise not subject to liability.

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**MEDICINE MAN TECHNOLOGIES, INC.**

Dated: August 17, 2017

By: /s/ Brett Roper  
Brett Roper  
Chief Executive Officer

Dated: August 17, 2017

By: /s/ Jonathan Sandberg  
Jonathan Sandberg  
Chief Financial Officer

**CERTIFICATION PURSUANT TO  
18 USC, SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 302 OF THE SARBANES OXLEY ACT OF 2002**

I, Brett Roper, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Medicine Man Technologies, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: August 17, 2017

/s/ Brett Roper  
\_\_\_\_\_  
Brett Roper, Chief Executive Officer

**CERTIFICATION PURSUANT TO  
18 USC, SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 302 OF THE SARBANES OXLEY ACT OF 2002**

I, Jonathan Sandberg, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Medicine Man Technologies, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: August 17, 2017

/s/ Jonathan Sandberg  
Jonathan Sandberg, Chief Financial Officer

**CERTIFICATION PURSUANT TO  
18 USC, SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with this quarterly report of Medicine Man Technologies, Inc. (the "Company") on Form 10-Q for the quarter ended June 30, 2017, as filed with the Securities and Exchange Commission on August 17, 2017 (the "Report"), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

1. The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 17, 2017

/s/ Brett Roper  
\_\_\_\_\_  
Brett Roper, Chief Executive Officer

Dated: August 17, 2017

/s/ Jonathan Sandberg  
\_\_\_\_\_  
Jonathan Sandberg, Chief Financial Officer



## Medicine Man Technologies Reports Second Quarter 2017 Results

DENVER, CO, August 17, 2017 -- Medicine Man Technologies Inc. (OTCQB: MDCL), one of the United States' leading cannabis branding and consulting companies, reported financial results for the quarter ended June 30, 2017.

### Financial and Business Highlights:

- Revenues increased by 489% to \$882,353 in the second quarter of 2017, from \$149,766 in the corresponding period in 2016, driven by higher consulting-based revenues and the contribution of the newly acquired Pono Publications and Success Nutrient businesses
- The acquisitions of Pono Publications and Success Nutrients provide industry leading cannabis cultivation technologies and products. These businesses generated \$352,158 of revenue in the second quarter of 2017, providing full-quarter contributions to Company revenue
- Brett Roper named as Chief Executive Officer at the first annual shareholders meeting, replacing Andrew Williams who assumed Brett Roper's prior role as Chairperson of the Board of Directors
- Named recognized cannabis cultivation expert, Joshua Haupt, as Chief Cultivation Officer
- The Company experienced extraordinary one-time expenses related to acquisition costs and stock compensation totaling \$4,579,019, which accounted for more than the entire net loss in the second quarter of 2017
- Subsequent to the end of the second quarter, Medicine Man completed the acquisition of Denver Consulting Group in July 2017
- Demand for services and recent acquisitions have allowed our Company to grow from 5 full time and 2 part time positions at year end 2016 to 19 full time and 2 part time positions as of this date
- We have increased our Board of Directors to five persons, three of which are independent and held our first annual shareholder meeting in Denver on June 3, 2017

“We are pleased with our second quarter results, which reflect the integration of Pono Publications, led by its flagship the *Three A Light*<sup>TM</sup> publication and Success Nutrients into Medicine Man Technologies,” commented Brett Roper, Chief Executive Officer of the Company. “We view these acquisitions as transformational, as not only do these businesses provide the Company with industry leading cultivation methodologies that we are already leveraging across our broad range of product and consulting services offerings, but also bring Joshua Haupt, their founder and a world-renowned cannabis cultivation thought leader, to Medicine Man Technologies as our Chief Cultivation Officer. We look forward to continuing to execute on our Brand Warehouse acquisition strategy, seeking synergistic companies across the cannabis industry that can support our U.S. and international expansion plan,” concluded Mr. Roper.

### Business Highlights

During the second quarter of 2017, Medicine Man added 13 new clients, spanning the states of Florida, Arkansas, Ohio, Michigan, Nevada, and California. Subsequent to the end of the quarter, the Company added one Ohio based processing application group, three Arkansas based dispensary application groups, two Florida based application groups, and two Michigan cultivation/processor application group, and one Canadian cultivation entity bringing our total active clients number (including DCG Legacy Clients) up to 44. Revenue generation for the Company is expected to run through the entirety of the general application process as determined by each state.

The initial Cultivation Max harvest clients in Nevada are expected later in the third quarter of 2017, from which Medicine Man expects to earn initial revenues beginning in the fourth quarter of this year.

The Company remains encouraged by the prospects for rapid expansion of its product and service footprint resulting from recent acquisitions. Medicine Man continues to experience a robust pace of inquiries on the west coast and elsewhere in the United States for its services, driven by its Denver Consulting Group division, the Company's internal marketing and event presence, and its *Three A Light* publication and Success Nutrients business presence.

### Results of Operations for the three months ended June 30, 2017 and 2016

During the three months ended June 30, 2017, Medicine Man generated revenues of \$882,353, which represented an increase of 489% over the same period in 2016. Second quarter 2017 revenue consisted of consulting/licensing fees of \$527,895, product sales of \$352,158 and the balance from fees arising from our participation in cannabis seminars. In the three months ended June 30, 2016, revenue totaled \$149,766, consisting of \$142,986 from consulting/licensing fees, and the balance from seminars.

Cost of services, consisting of expense related to delivery of services and product procurement, was \$272,001 during the three months ended June 30, 2017, compared to \$44,177 during the comparable period in 2016, with the increase largely attributable to the addition of product procurement expenses and increases in wages. The Company notes that during the second quarter of 2017, Medicine Man had eight full-time and two part-time employees, as compared to three full-time and two part-time employees in the second quarter of 2016.

Operating expenses during the three months ended June 30, 2017, were \$5,172,869, including a one-time stock compensation expense of \$4,480,318, compared with \$207,059 in the corresponding period in 2016. General and administrative expense in the three months ended June 30, 2017 totaled \$331,425, compared to \$197,879 during the three months ended June 30, 2016. Increased operating expenses during the three months ended June 30, 2017 included professional fees of \$141,953 and advertising expense of \$56,025. Advertising expense during the three months ended June 30, 2016 totaled \$9,180. During the three months ended June 30, 2017, the Company incurred \$98,701 in one-time acquisition costs related to the Pono and Success acquisitions.

Net loss for the three months ended June 30, 2017 was \$4,494,435, or \$0.23 per share, compared to net loss of \$99,662, or \$0.01 per share, during the three months ended June 30, 2016, primarily due to one-time costs related to stock compensation.

#### Results of Operations for the six months ended June 30, 2017 and 2016

During the six months ended June 30, 2017, we generated revenues of \$1,423,489, which represented an increase of 307% over the same period in 2016. Six-month 2017 revenue consisted of consulting/licensing fees of \$1,067,109, product sales of \$352,158 and the balance of fees arising from our participation in cannabis seminars. In the six months ended June 30, 2016 revenue totaled \$349,381, consisting of \$337,221 from consulting/licensing fees, and the balance from seminars. This increase was due to the acquisition of Pono and Success, growth in our service model and growth within our client base.

Cost of services, consisting of expense related to delivery of services and product procurement, was \$437,160 during the six months ended June 30, 2017, compared to \$181,618 during the comparable period in 2016, with the increase largely attributable to the addition of product procurement expenses and increases in wages from an expanded employee base, as discussed earlier.

Operating expenses during the six months ended June 30, 2017, were \$5,401,754, including a one-time stock compensation expense of \$4,480,318. General and administrative expense were \$435,296, compared to \$312,217 during the six months ended June 30, 2016. Increased operating expenses during the six months ended June 30, 2017 included additional cost incurred related to professional fees of \$233,483, as well as \$89,509 in advertising expense, compared to advertising expenses of \$21,672 during the same period in 2016. The Company has increased its investment substantially in the Marijuana Business Daily conference offerings as well as publication platform based upon their continued growth in popularity and prospect generation capacities. During the six months ended June 30, 2017, the Company incurred \$98,701 in one-time acquisition costs related to the Pono and Success acquisition.

Net loss during the six months ended June 30, 2017 totaled \$4,383,271, or \$0.22 per share, compared to net loss of \$213,518, or \$0.02 per share, for the six months ended June 30, 2016, with the increase primarily driven by one-time stock-based compensation costs, as discussed above.

At June 30, 2017, the Company reported cash and cash equivalents of \$200,600, compared with \$351,524 at December 31, 2016. At June 30, 2017, receivables were \$231,399, compared with \$25,000 at June 30, 2016, with the increase attributable to collections of earned income that were due near the end of the quarter, that have been fully collected subsequent to the end of the quarter.

#### **About Medicine Man Technologies, Inc.**

Established in March 2014, the Company secured its first client/licensee in April 2014. To date, the Company has provided guidance for several clients that have successfully secured licenses to operate cannabis businesses within their state. It currently has twenty eight active clients in 12 states and Puerto Rico, focusing on working with clients to 1) utilize its experience, technology, and training to help secure a license in states with newly emerging regulations, 2) deploy the Company's highly effective variable capacity constant harvest cultivation practices through its deployment of Cultivation MAX, and eliminate the liability of single grower dependence, 3) avoid the costly mistakes generally made in start-up, 4) stay engaged with an ever expanding team of licensees and partners, all focused on quality and safety that will 'share' the ever-improving experience and knowledge of the network, and 5) continuing the expansion of its Brands Warehouse concept.

**Safe Harbor Statement**

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues and any payment of dividends on our common and preferred stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the Securities and Exchange Commission. Among other matters, the Medicine Man Technologies may not be able to sustain growth or achieve profitability based upon many factors including, but not limited to, general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing and new service lines, noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations where we will be providing services, the impact of which cannot be predicted at this time.

**Contact Information:**

KCSA Strategic Communications

MDCL@kcsa.com

**MEDICINE MAN TECHNOLOGIES, INC.**  
**STATEMENT OF COMPREHENSIVE (LOSS) AND INCOME**  
*For the Three and Six Months Ended June 30, 2017 and 2016*  
*Express in U.S. Dollars*

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June, 30</b>	
	<b>2017</b>	<b>2016</b>	<b>2017</b>	<b>2016</b>
<b>Operating revenues</b>				
Product sales	\$ 229,214	\$ –	\$ 229,214	\$ –
Product sales - related party	122,944	–	122,944	–
Licensing fees	301,313	142,986	501,313	337,221
Consulting fees	226,582	–	565,796	\$ –
Seminar fees	2,300	6,780	4,222	12,160
Total revenue	<u>882,353</u>	<u>149,766</u>	<u>1,423,489</u>	<u>349,381</u>
<b>Cost of services</b>				
Cost of services	\$ 245,965	\$ 44,177	\$ 411,124	\$ 181,618
Cost of services - related party	26,036	–	26,036	–
Total cost of services	<u>272,001</u>	<u>44,177</u>	<u>437,160</u>	<u>181,618</u>
<b>Gross profit</b>	<u>\$ 610,352</u>	<u>\$ 105,589</u>	<u>\$ 986,329</u>	<u>\$ 167,763</u>
<b>Operating expenses</b>				
General and administrative	\$ 331,425	\$ 197,879	\$ 435,296	\$ 312,217
Professional services	141,953	–	233,483	–
One-time Acquisition costs	98,701	–	98,701	–
Stock based compensation expense	4,480,318	–	4,480,318	49,200
Advertising	56,025	9,180	89,509	21,672
Salaries	64,447	–	64,447	–
Total operating expenses	<u>\$ 5,172,869</u>	<u>\$ 207,059</u>	<u>\$ 5,401,754</u>	<u>\$ 383,089</u>
<b>Income from operations</b>	<u>\$ (4,562,517)</u>	<u>\$ (101,470)</u>	<u>\$ (4,415,425)</u>	<u>\$ (215,326)</u>
<b>Other income/expense</b>				
Interest income	\$ (7,480)	\$ (1,808)	\$ (14,877)	\$ (1,808)
Net gain on derivative	(82,373)	–	(131,382)	–
Interest expense related to convertible notes	21,990	–	44,329	–
Loss on management fee contracts	–	–	70,257	–
Net unrealized (loss) on available for sale securities	–	–	(262)	–
Other income	(219)	–	(219)	–
Total other expense	<u>(68,082)</u>	<u>(1,808)</u>	<u>(32,154)</u>	<u>(1,808)</u>
<b>Net income (loss)</b>	<u>\$ (4,494,435)</u>	<u>\$ (99,662)</u>	<u>\$ (4,383,271)</u>	<u>\$ (213,518)</u>
<b>Earnings per share attributable to common shareholders:</b>				
Basic and diluted (loss)/earnings per share	\$ (0.23)	\$ (0.01)	\$ (0.22)	\$ (0.02)
Weighted average number of shares outstanding - basic and diluted	19,548,087	10,092,500	19,548,087	10,031,875
<b>Other comprehensive income (loss), net of tax</b>				
Net unrealized (loss) on available for sale securities	(9,248)	(16,000)	(10,551)	(5,600)
Total other comprehensive income (loss), net of tax	<u>(9,248)</u>	<u>(16,000)</u>	<u>(10,551)</u>	<u>(5,600)</u>
<b>Comprehensive gain (loss)</b>	<u>\$ (4,503,683)</u>	<u>\$ (115,662)</u>	<u>\$ (4,393,822)</u>	<u>\$ (219,118)</u>

**MEDICINE MAN TECHNOLOGIES, INC.**  
**BALANCE SHEETS**  
*Express in U.S. Dollars*

	<u>June 30, 2017</u>	<u>December 31, 2016</u>
<b>Assets</b>		
<b>Current assets</b>		
Cash and cash equivalents	\$ 200,600	\$ 351,524
Accounts receivable, net	231,399	25,000
Accounts receivable - related party	24,294	-
Available for sale securities	17,701	13,998
Short-term note receivable	278,893	264,016
Inventory	109,174	-
Other assets	50,006	27,479
Total current assets	912,067	682,017
<b>Non-current assets</b>		
Fixed assets, net accumulated depreciation of \$46,278	\$ 154,033	\$ 42,126
Intangible assets, net accumulated amortization of \$3,055	72,869	3,708
Goodwill	6,301,080	-
Total non-current assets	6,527,982	45,834
<b>Total assets</b>	<b>\$ 7,440,049</b>	<b>\$ 727,851</b>
<b>Liabilities and Stockholders' Equity</b>		
<b>Current liabilities</b>		
Accounts payable	\$ 32,328	\$ -
Derivative liability	23,017	294,002
Other liabilities	10,713	175
Total current liabilities	66,058	294,177
<b>Long-term liabilities</b>		
Note payable - related party	\$ 58,280	\$ -
Convertible loan	675,000	810,000
Total long-term liabilities	733,280	810,000
<b>Total liabilities</b>	<b>799,338</b>	<b>1,104,177</b>
Commitments and contingencies, note 13		
<b>Shareholders' equity</b>		
Common stock \$0.001 par value, 90,000,000 authorized, 18,948,087 and 10,402,500 were issued and outstanding June 30, 2017 and December 31, 2016, respectively	\$ 19,118	\$ 10,403
Additional paid-in capital	10,327,876	1,026,052
Additional paid-in capital - Warrants	2,100,318	-
Accumulated other comprehensive income (loss)	(14,854)	(4,303)
Retained earnings	(5,791,747)	(1,408,478)
Total shareholders' equity	6,640,711	(376,326)
<b>Total liabilities and stockholders' equity</b>	<b>\$ 7,440,049</b>	<b>\$ 727,851</b>

**MEDICINE MAN TECHNOLOGIES, INC.**  
**STATEMENT OF CASH FLOWS**  
*For the Six Months Ended June 30, 2017 and 2016*  
*Expressed in U.S. Dollars*

	<u>2017</u>	<u>2016</u>
<b>Cash flows from operating activities</b>		
Net income for the period	\$ (4,383,271)	\$ (213,518)
Adjustments to reconcile net income to net cash provided by operating activities		
Loss (gain) on derivative, net	(131,382)	-
Stock based compensation	4,480,318	49,200
Depreciation and amortization	24,822	8,531
Changes in operating assets and liabilities		
Short term note receivable	(14,877)	(100,000)
Accounts receivable	(230,693)	70,447
Inventory	(109,174)	-
Other assets	(83,085)	(26,765)
Accounts payable and other liabilities	99,725	(12,429)
<b>Net cash used from operating activities</b>	<u>(347,617)</u>	<u>(224,534)</u>
<b>Cash flows from investing activities</b>		
Purchase of assets	\$ (205,890)	\$ -
Proceeds from AFS securities, net	(10,551)	-
Acquisition investment	233,357	-
<b>Net cash earned in investing activities</b>	<u>16,916</u>	<u>-</u>
<b>Cash flows from financing activities</b>		
Cash raised by sale of convertible debt	179,777	-
<b>Net cash earned for financing activities</b>	<u>179,777</u>	<u>-</u>
Net decrease in cash and cash equivalents	\$ (150,924)	\$ (224,534)
Cash and cash equivalents - beginning of year	351,524	262,146
<b>Cash and cash equivalents - end of year</b>	<u>\$ 200,600</u>	<u>\$ 37,612</u>
<b>Non-Cash Transactions</b>		
Acquisition investment	\$ 233,357	\$ -